Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
AbbVie Inc. (NYSE: ABBV) shares increased 2.25 percent to close at $43.68 a share Monday. The stock traded between $42.82 and $43.69 on volume of 3.98 million shares traded. Morgan Stanley has recently upgraded the company’s rating to “overweight” from “equal weight”. Shares of AbbVie have gained approximately 27.8 percent year-to-date.
Find out more about AbbVie including full access to the free equity report at:
www.RDInvesting.com/ABBV
Bank of America Corp. (NYSE: BAC) shares gained 1.68 percent to close at $13.28 a share Monday. The stock traded between $13.08 and $13.37 on volume of 107.44 million shares traded. Morgan Stanley has recently upgraded the company’s rating to “overweight” and current have a price target of 16.00 on the stock. Shares of Bank of America have gained approximately 14.4 percent year-to-date.
Find out more about Bank of America including full access to the free equity report at:
www.RDInvesting.com/BAC
Caterpillar Inc. (NYSE: CAT) shares increased 1.29 percent to close at $83.20 a share Monday. The stock traded in between $82.25 and $83.20 on volume of 4.88 million shares traded. JPMorgan Chase & Co. have recently upgraded the company’s rating to “overweight” from “neutral” and currently have a price target of $100.00 on the stock. Shares of Caterpillar are down approximately 7.0 percent year-to-date.
Find out more about Caterpillar including full access to the free equity report at:
www.RDInvesting.com/CAT
Edwards Lifesciences Corp. (NYSE: EW) shares gained 0.32 percent to close at $66.81 a share Monday. The stock traded in between $66.55 and $67.65 on volume of 804,841 shares traded. Credit Suisse has recently upgraded the company’s rating to “outperform” from “neutral”. Shares of Edwards Lifesciences have fallen approximately 26.0 percent year-to-date.
Find out more about Edwards Lifesciences including full access to the free equity report at:
www.RDInvesting.com/EW
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]